The public market version of the GLP-1 trade is pretty well understood by now. Alcohol stocks sold off, food companies got repriced, and Eli Lilly became one of the most valuable companies in the world. JPMorgan estimates these drugs could pull $30 to $55 billion a year out of US food and drink spending by 2030.
The private market story is much newer.
Read MoreBOULDER, Colo., March 31, 2026 -- Ambrosia Biosciences Inc. (“Ambrosia”) today announced a $100 million oversubscribed Series B financing. The financing provides $100 million in committed capital, intended to fund the Company through clinical trial initiation of its oral small molecule GLP-1. The financing was co-led by new investors Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital. Existing investors BVF Partners and Boulder Ventures also participated, and were joined by additional new investors Janus Henderson Investors, Samsara BioCapital, and an undisclosed institutional investor.
Read MoreDrugs that mimic glucagonlike peptide-1 (GLP-1), such as semaglutide—marketed as Ozempic or Wegovy—have revolutionized the treatment of obesity and type 2 diabetes, but they have major drawbacks. “[They] are expensive to manufacture, they have to be refrigerated, and they often have to be injected because they cannot go through the gastrointestinal tract without being degraded,” explains Alejandra Tomas, a cell biologist at Imperial College London who studies the cellular receptor GLP-1 drugs target. That’s all because they consist of peptides, or long chains of amino acids.
Read MoreBoulder, CO – December 10th, 2024 – Ambrosia Biosciences Inc. (“Ambrosia”), today announced the successful second closing of its Series A financing. This closing was led by Merck, known as MSD outside the United States and Canada, with additional participation from existing investors BVF Partners and Boulder Ventures. This additional capital brings Ambrosia’s total Series A financing to $25MM.
Read MoreBoulder, CO – August 20, 2024 – Ambrosia Biosciences Inc. (“Ambrosia” or “the Company”), today announced the successful first closing of its Series A financing. The financing totaled $16 Million and was led by BVF Partners and Boulder Ventures. Ambrosia’s financing will be used to scale up its drug discovery programs and laboratory operations in Boulder, CO.
Read More
